Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
ESMO Congress 2025
ACS Clinical Congress 2025
2025 ASCO Quality Care Symposium
2025 ASTRO Annual Meeting
2025 Debates and Didactics in Hematology and Oncology
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
No results found for covid 1
Suggestions:
Ensure words are spelled correctly.
Try rephrasing keywords or using synonyms.
Try less specific keywords.
«
1
»
Advertisement
Advertisement
Oct
31
Today In Oncology
Novel Strategy May Improve Outcomes in Patients With Treatment Resistant DLBCL
CAR T Cell Therapy May Be Effective but Unaffordable as Second Line Therapy for Patients With DLBCL
Second-Line Lisocabtagene Maraleucel May Be More Cost-Effective Than Standard-Care DLBCL Therapy
Combination Targeted Therapy Produces Durable Responses in Patients With Relapsed DLBCL
Shortening FDA Mandated CAR T Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL
View More
Advertisement
